PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer.
Elizabeth A SadowskiAli PirastehAlan B McMillanKathryn J FowlerJoanna E KusmirekPublished in: Abdominal radiology (New York) (2021)
Positron emission tomography/magnetic resonance imaging (PET/MR) is used in the pre-treatment and surveillance settings to evaluate women with gynecologic malignancies, including uterine, cervical, vaginal and vulvar cancers. PET/MR combines the excellent spatial and contrast resolution of MR imaging for gynecologic tissues, with the functional metabolic information of PET, to aid in a more accurate assessment of local disease extent and distant metastatic disease. In this review, the optimal protocol and utility of whole-body PET/MR imaging in patients with gynecologic malignancies will be discussed, with an emphasis on the advantages of PET/MR over PET/CT and how to differentiate normal or benign gynecologic tissues from cancer in the pelvis.
Keyphrases
- positron emission tomography
- pet ct
- contrast enhanced
- computed tomography
- magnetic resonance imaging
- papillary thyroid
- pet imaging
- endometrial cancer
- magnetic resonance
- squamous cell
- diffusion weighted imaging
- squamous cell carcinoma
- gene expression
- small cell lung cancer
- childhood cancer
- randomized controlled trial
- healthcare
- mass spectrometry
- lymph node
- public health
- radiation therapy
- rectal cancer
- single molecule
- young adults
- clinical evaluation